Short-term clinical outcomes of cytoreductive radical prostatectomy combined with abiraterone-based androgen deprivation therapy in oligometastatic prostate cancer
Retrospective cohort study evaluates improved outcomes in oligometastatic prostate cancer using combined treatments, suggesting enhanced disease control.
Key Points
The study aims to assess the short-term efficacy of combining cytoreductive radical prostatectomy with pharmacotherapy in patients with oligometastatic prostate cancer.
Retrospective cohort study including 94 oligometastatic prostate cancer patients treated from January 2023 to December 2023.
Patients categorized into a pharmacotherapy group (control) and a combined treatment group (CRP with pharmacotherapy).
Clinical outcomes evaluated including PSA levels, quality of life, and complications over 24 months.
The combined treatment group exhibited a higher proportion of complete/partial responses and longer progression-free survival.
Significant reductions in prostate-specific antigen levels were noted at the 2-month mark in the combined treatment group.
Post-treatment quality of life scores improved in the combined group, with lower pain and anxiety levels observed.